GPs face escalating litigation
نویسندگان
چکیده
منابع مشابه
A feasibility test of using smartphones to collect GPS information in face-to-face surveys
A feasibility test of using smartphones to collect GPS information in face-to-face surveys" (2015). Survey organizations rely on interviewers to make informed and efficient decisions about their efforts in the field, including which housing units they approach to knock on doors, seeking to make appointments, and obtain interviews. This paper presents initial findings from a feasibility test on ...
متن کاملLitigation After Nasal Plastic Surgery
Introduction: Esthetic surgeries are among the commonest medical procedures in the world nowadays; and as statistics declare, there has been a rapid increase in the rate of rhinoplasty during the recent years. Hence, as the number of cosmetic surgeries rises, the increment in the number of physicians being sued is quite inevitable; either due to complication in rhinoplasties or even inability ...
متن کاملNo news is good news: voluntary disclosure in the face of litigation
We study disclosure dynamics when the firm value evolves stochastically over time. The presence of litigation risk, arising from the failure to disclose unfavorable information, crowds out positive disclosures. Litigation risk mitigates firms’ tendency to use inefficient disclosure policies. From a policy perspective, we show that a stricter legal environment may be an efficient way to stimulat...
متن کاملDetecting Privilege-Escalating Executable Exploits
The Lincoln Laboratory Malicious Code Detector (LIMACODE) is a system for statically detecting privilege-escalating exploits in data streams, such as files and network traffic. LIMACODE operates as follows: it scans data streams, identifies the language of the stream, then extracts language-specific features for input to a feed-forward neural network classifier which labels the stream as either...
متن کاملEscalating and de-escalating treatment in HER2-positive early breast cancer.
The current standard adjuvant systemic treatment of early HER2-positive breast cancer consists of chemotherapy plus 12months of trastuzumab, with or without endocrine therapy. Several trials have investigated modifications of the standard treatment that are shorter and less resource-demanding (de-escalation) or regimens that aim at dual HER2 inhibition or include longer than 12months of HER2-ta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1999
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.318.7187.830b